Seegene, Inc. (096530.KQ)
KRW 25350.0
(1.2%)
KRW 25350.0
(1.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -30 Billion KRW | -116.59% |
| 2022 | 180.92 Billion KRW | -72.86% |
| 2021 | 666.65 Billion KRW | -1.41% |
| 2020 | 676.18 Billion KRW | 2915.59% |
| 2019 | 22.42 Billion KRW | 118.4% |
| 2018 | 10.26 Billion KRW | 37.14% |
| 2017 | 7.48 Billion KRW | -25.75% |
| 2016 | 10.08 Billion KRW | 16.75% |
| 2015 | 8.63 Billion KRW | -22.33% |
| 2014 | 11.11 Billion KRW | -21.08% |
| 2013 | 14.08 Billion KRW | 15.24% |
| 2012 | 12.22 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -14.36 Billion KRW | -512.08% |
| 2024 Q2 | -1.12 Billion KRW | 92.14% |
| 2023 Q2 | -9.65 Billion KRW | 29.86% |
| 2023 Q1 | -13.75 Billion KRW | -185.59% |
| 2023 FY | -30 Billion KRW | -116.59% |
| 2023 Q4 | 3.48 Billion KRW | 134.57% |
| 2023 Q3 | -10.08 Billion KRW | -4.49% |
| 2022 Q3 | -47.82 Billion KRW | -467.89% |
| 2022 Q2 | 13 Billion KRW | -93.49% |
| 2022 Q4 | 16.07 Billion KRW | 133.61% |
| 2022 Q1 | 199.67 Billion KRW | -0.13% |
| 2022 FY | 180.92 Billion KRW | -72.86% |
| 2021 Q1 | 193.93 Billion KRW | -24.69% |
| 2021 Q3 | 128.6 Billion KRW | -10.8% |
| 2021 FY | 666.65 Billion KRW | -1.41% |
| 2021 Q4 | 199.92 Billion KRW | 55.45% |
| 2021 Q2 | 144.18 Billion KRW | -25.65% |
| 2020 Q1 | 39.75 Billion KRW | 675.26% |
| 2020 Q3 | 209.94 Billion KRW | 24.24% |
| 2020 Q4 | 257.51 Billion KRW | 22.66% |
| 2020 FY | 676.18 Billion KRW | 2915.59% |
| 2020 Q2 | 168.98 Billion KRW | 325.07% |
| 2019 FY | 22.42 Billion KRW | 118.4% |
| 2019 Q3 | 6.84 Billion KRW | 47.43% |
| 2019 Q4 | 5.12 Billion KRW | -25.08% |
| 2019 Q2 | 4.64 Billion KRW | -20.08% |
| 2019 Q1 | 5.8 Billion KRW | 16.8% |
| 2018 Q1 | 1.06 Billion KRW | -66.97% |
| 2018 FY | 10.26 Billion KRW | 37.14% |
| 2018 Q4 | 4.97 Billion KRW | 74.48% |
| 2018 Q3 | 2.85 Billion KRW | 106.17% |
| 2018 Q2 | 1.38 Billion KRW | 30.34% |
| 2017 Q3 | 1.54 Billion KRW | 311.27% |
| 2017 Q2 | -729.33 Million KRW | -121.06% |
| 2017 Q1 | 3.46 Billion KRW | 39.38% |
| 2017 Q4 | 3.21 Billion KRW | 108.41% |
| 2017 FY | 7.48 Billion KRW | -25.75% |
| 2016 FY | 10.08 Billion KRW | 16.75% |
| 2016 Q1 | 1.94 Billion KRW | -16.2% |
| 2016 Q2 | 2.76 Billion KRW | 42.63% |
| 2016 Q3 | 2.88 Billion KRW | 4.32% |
| 2016 Q4 | 2.48 Billion KRW | -13.97% |
| 2015 Q2 | 1.94 Billion KRW | -35.17% |
| 2015 Q1 | 3 Billion KRW | 42.57% |
| 2015 Q4 | 2.31 Billion KRW | 70.01% |
| 2015 FY | 8.63 Billion KRW | -22.33% |
| 2015 Q3 | 1.36 Billion KRW | -30.12% |
| 2014 Q1 | 2.72 Billion KRW | -27.91% |
| 2014 FY | 11.11 Billion KRW | -21.08% |
| 2014 Q4 | 2.1 Billion KRW | -17.16% |
| 2014 Q3 | 2.54 Billion KRW | -31.94% |
| 2014 Q2 | 3.74 Billion KRW | 37.42% |
| 2013 Q4 | 3.77 Billion KRW | -11.91% |
| 2013 Q2 | 3.66 Billion KRW | 55.01% |
| 2013 FY | 14.08 Billion KRW | 15.24% |
| 2013 Q3 | 4.28 Billion KRW | 17.02% |
| 2013 Q1 | 2.36 Billion KRW | -43.31% |
| 2012 Q4 | 4.16 Billion KRW | 122.42% |
| 2012 Q3 | 1.87 Billion KRW | 0.0% |
| 2012 FY | 12.22 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 142.82 Billion KRW | 121.01% |
| InBody Co.,Ltd | 44.46 Billion KRW | 167.484% |
| Curexo Inc. | 1.13 Billion KRW | 2742.908% |
| i-SENS, Inc. | 10.92 Billion KRW | 374.567% |
| Ray Co., Ltd. | 6.11 Billion KRW | 590.469% |
| Gencurix Inc. | -12.37 Billion KRW | -142.475% |
| Sugentech Inc. | -22.74 Billion KRW | -31.953% |
| L&C Bio Co., Ltd | 6.66 Billion KRW | 550.118% |